Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFEST statin discontinuation/non-initiation after ischemic stroke or transient ischemic attack in frail older adults
NL-OMON59193Phase 4Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atorvastatin in ischemic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Daily functioning at 2 years and Health-related quality of life at 2 years. Planned start Feb 2023; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on NL-OMON59193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59193.